Navigation Links
Perrigo Confirms FDA Approval For Testosterone Gel 1%
Date:2/5/2013

ALLEGAN, Mich., Feb. 5, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application (NDA) for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel® 1%.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

AndroGel® 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were approximately $705 million annually, as measured by Symphony Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."          

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
2. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
3. Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%
4. Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013
5. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
6. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
7. Perrigo Company To Present At The Credit Suisse Healthcare Conference
8. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
9. Perrigo Company Announces Appointment Of New Board Of Directors Member
10. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
11. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , February 23, 2017 On Wednesday, ... day as four out of nine sectors finished the trading ... managed a flat closing. Major US indices were also mixed ... the day at 5,860.63, slightly down by 0.09%; the Dow ... and the S&P 500 closed at 2,362.82, down 0.11%. This ...
(Date:2/23/2017)... , February 23, 2017 ML Capital ... in Colorado Highlife Tours , a ... plan in partnership with Puration, Inc. (USOTC: PURA) to enter ... cannabis tours product. The Colorado Highlife Tours acquisition announced today is ... tourism strategy. ...
(Date:2/23/2017)... VANCOUVER, British Columbia , Feb. 23, 2017 ... today announced its year end 2016 financial results.  ... 2017, OncoGenex, and Achieve Life Science, Inc., a privately held ... a definitive merger agreement under which OncoGenex will acquire ... proposed merger, Achieve,s stockholders are expected to own 75% ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... ... the perfect opportunity for the nation to come together to ... basketball bracket – with its favorite fruit – apples! To ... apple lovers to join the “Apple Madness” bracket tournament – ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing ... sit stand solutions representative to the Minneapolis Home and Garden Show which is being ... that is garnering national attention is the Minneapolis Convention Center. , From its ...
(Date:2/22/2017)... ... February 22, 2017 , ... Our high-octane society demands ... the sharpest brain. , Power On, a mental performance enhancer from Modus Nutrition, ... brain. Each capsule contains Cognizin® Citicoline, a branded form of the brain health ...
(Date:2/22/2017)... ... 2017 , ... Secure Exchange Solutions, the leading provider of ... health information exchanges, physicians and patients, announced today that SES Direct earned the ... IT Module Certification via Drummond Group LLC, an Authorized Certification Body (ACB). This ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leverages advanced data analytics to accurately understand each Medicare Advantage member’s risk, ... a given population. This new solution helps transform the HCC Risk Adjustment ...
Breaking Medicine News(10 mins):